SBFM

SBFM

USD

Sunshine Biopharma Inc. Common Stock

$1.730+0.080 (4.848%)

Prix en Temps Réel

Healthcare
Drug Manufacturers - Specialty & Generic
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$1.650

Haut

$1.730

Bas

$1.650

Volume

0.07M

Fondamentaux de l'Entreprise

Capitalisation Boursière

8.5M

Industrie

Drug Manufacturers - Specialty & Generic

Pays

United States

Statistiques de Trading

Volume Moyen

0.73M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $1.169Actuel $1.730Haut $3.9

Actualités Connexes

AccessWire

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma is quickly establishing which side of that line it's on. After

Voir plus
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
AccessWire

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. , a leading pharmaceutical company focused on innovative and affordable healthcare solutions,

Voir plus
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
AccessWire

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma is quietly engineering a flywheel model for biotech. Not a flashy one that spins fast and burns energy and cash quickly. A lean

Voir plus
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
AccessWire

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma is the kind of company that keeps the market honest. On paper, it's small, barely a rounding error next to the giants of

Voir plus
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Analyst Upgrades

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma with a Buy and maintains $7 price target.

Voir plus
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.